European Silent heart attack Market Size, Share & Trends Analysis Report by Diagnosis (Electrocardiography (ECG), MRI, Computed Tomography (CT Scan), Echocardiography, and Others), by Treatment (Medication and Surgery), and by End-Users (Hospitals & Clinics and Ambulatory Surgical Centers) and Forecast, 2020-2026.
European silent heart attack market is estimated to grow modestly, at a CAGR of around 6.5%, during the forecast period. The huge demand for cardiology surgeries and devices and growing lifestyle-oriented diseases such as CVD, CHD, stroke, and other heart related diseases are offering growth to the market in the region. Europe has quality healthcare system; however, the surgeries and medical devices are costly. In Europe, in April 2019, Britain heart Foundation has launched a global competition namely “The Big Bit Challenge” with the prize amounting to $39 million to propose a transformational solution to any CVD disease. Europe has a huge economic burden of lifestyle-oriented diseases such as CVD, CHD, MI treatment, stroke, and other heart diseases. Moreover, Europe region which includes UK, Spain, Germany, France, Italy, Sweden, and other EU countries have significant number of CVD patients with heart diseases which is giving rise to the adoption of robotic surgeries and hybrid operating rooms.
European silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). ECG is the most used technology to diagnose silent heart attack. ECG provides insights about heart rate, indicates, if there is enlargement of the heart due to high blood pressure (hypertension) or evidence of a previous heart attack.
The companies which are contributing to the growth of the European silent heart attack market include AstraZeneca PLC, Bayer AG, Siemens AG, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, and GlaxoSmithKline Plc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the European silent heart attack market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
1. European Silent heart attack Market Research and Analysis by Diagnosis
2. European Silent heart attack Market Research and Analysis by Treatment
3. European Silent heart attack Market Research and Analysis by End-Users
The Report Covers
European silent heart attack market is estimated to grow modestly, at a CAGR of around 6.5%, during the forecast period. The huge demand for cardiology surgeries and devices and growing lifestyle-oriented diseases such as CVD, CHD, stroke, and other heart related diseases are offering growth to the market in the region. Europe has quality healthcare system; however, the surgeries and medical devices are costly. In Europe, in April 2019, Britain heart Foundation has launched a global competition namely “The Big Bit Challenge” with the prize amounting to $39 million to propose a transformational solution to any CVD disease. Europe has a huge economic burden of lifestyle-oriented diseases such as CVD, CHD, MI treatment, stroke, and other heart diseases. Moreover, Europe region which includes UK, Spain, Germany, France, Italy, Sweden, and other EU countries have significant number of CVD patients with heart diseases which is giving rise to the adoption of robotic surgeries and hybrid operating rooms.
European silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). ECG is the most used technology to diagnose silent heart attack. ECG provides insights about heart rate, indicates, if there is enlargement of the heart due to high blood pressure (hypertension) or evidence of a previous heart attack.
The companies which are contributing to the growth of the European silent heart attack market include AstraZeneca PLC, Bayer AG, Siemens AG, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, and GlaxoSmithKline Plc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the European silent heart attack market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
1. European Silent heart attack Market Research and Analysis by Diagnosis
2. European Silent heart attack Market Research and Analysis by Treatment
3. European Silent heart attack Market Research and Analysis by End-Users
The Report Covers
- Comprehensive research methodology of the European silent heart attack market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European silent heart attack market.
- Insights about market determinants which are stimulating the European silent heart attack market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Boston Scientific Corp.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Medtronic PLC
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Siemens AG
- Takeda Pharmaceutical Co. Ltd.